Strong Support for Grifols Citigroup Analysts, The American firm has decided to raise target price shares of blood products company up to 23 eurosFrom last 22.30 Euro.
Considering Tuesday’s close at 11.19 euros for Grifols, Citigroup’s new valuation means 105% capacity, In other words, experts at Bank of America see the stock as more than double its price 12 months ahead.
However, Citi is one of the most optimistic research institutes covering Grifols. According to data compiled by Reuters, analysts on average recommend a ‘buy’ on the stock with a price target of 17.14 euros, a 53% upside from the current price.
Grifols shares have accumulated a revaluation of 3.20% so far this year, with a market capitalization of 4,740 million euros. However, this prudent behavior changes significantly if the focus is placed only on the past 20 sessions, with a revaluation over that period of 19.7%.
Having confirmed this, the change of course in the last week appears to go hand in hand with the revolution at its peak Thomas Glanzmann has combined the position of CEO with that of executive chairman. that he has already practiced
as explained “The market is betting on a new era for the company,” Maria Mira, EI’s fundamental analyst, said., In his opinion, “the market is pushing for a restructuring of the management team and perhaps announcing a possible corporate deleveraging operation before the end of 2023, on the other hand should be imperative given its huge debt, at 9,350.8 million euros.” March At the end of “.
Register for free in investment strategies and Discover the fastest growing stocks in the stock market right now, Adjusted prices, good fundamentals and a bullish trend.
You’ll also have access to our stock market analysis newsletter, you’ll enjoy our favorite securities tools and you’ll be able to take our free training courses. Register for free here.